Recent advances in the use of legume lectins for the diagnosis and treatment of breast cancer

Amphiphilic Low-Molecular-Weight Gelators Bearing β-S-N-Acetylglucosamine Linked to a Tartaric Acid Scaffold: Synthesis, Self-Assembly and Wheat Germ Agglutinin Binding

The self-assembly of carbohydrate-based amphiphiles can lead to colloidal soft materials such as supramolecular gels featuring highly desirable characteristics like biodegradability and biocompatibility. The report herein presents the synthesis, characterization and supramolecular self-assembly, physical gelation and wheat lectin binding of two structurally related amphiphilic compounds having β-S-N-acetylglucosamine residues linked to a 2,3-diacyl-N,N'-dipropargylated-l-tartaric diamide. A 1-thio-β-N-acetyl-d-glucosamine precursor attached to a conveniently functionalized linker with an azido group was synthesized by means of a one-pot procedure followed by deprotection. A click reaction successfully led to the two amphiphiles, which differed in length of the fatty acid attached to the tartaric acid scaffold. Although both compounds are poorly soluble in water and organic solvents, the difference in terms of hydrophilic moieties provided them with distinct supramolecular gelation properties. While the presence of an octadecyl chain produced a hydrogelator, the dodecadecyl homologue would only form weak gels in DMSO. SEM and rheology experiments confirmed the characteristic fibrillar morphology and viscoelastic properties, in agreement with the presence of physical gels. Both amphiphiles were able to interact reversibly with wheat germ agglutinin (WGA), a lectin that specifically recognizes GlcNAc residues, indicating a potential use in the food industry, as a gluten sensitivity manager, as well as in health-related industries, for example, for drug delivery systems.

Therapeutic potential of lectins in the treatment of breast cancer: A review

Breast cancer is one of the most common malignancies and the leading cause of cancer-related deaths in women. There are 3 major subtypes of breast cancer that are distinguished by expression of estrogen or progesterone receptors and ERBB2 gene amplification. The 3 subtypes have different risk profiles and treatment strategies. Abnormal glycosylation is thought to play an important role in the development of the tumorigenic and metastatic phenotype of breast cancer and resistance to therapy. They may also be a potentially attractive target for breast cancer treatment. Proteins such as lectins, a family of carbohydrate-binding proteins found in a variety of organisms from viruses to humans, can specifically interact with abnormally glycosylated carbohydrate residues in cancer cells and induce cytotoxic effects. In recent years, there has been a growing number of research addressing studies demonstrating their antitumorigenic and antimalignant effects. This review summarizes recent findings on lectins from plants, animals, fungi, and bacteria that are potentially therapeutic agents against breast cancer and outlines the basis of their mechanism of action.